Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
Authors:
- Mariano A Garcia-BlancoMGMariano A Garcia-Blanco
- Andrew J ArmstrongAAAndrew J Armstrong
- Scott M DehmScott M Dehm
Open Access
- 1 August 2014
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 21 (4) , T87-T103
Abstract
As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form, genetic and epigenetic adaptation, clonal selection, and evolution of the tumor microenvironment contribute to the emergence of unique biological characteristics under the selective pressure of external stresses. These stresses include the therapies applied in the clinic or laboratory and the exposures of cancers to hormonal, paracrine, or autocrine stimuli in the context of the tumor micro- and macro-environment. The androgen receptor (AR) is a key gene involved in PCa etiology and oncogenesis, including disease development, progression, response to initial hormonal therapies, and subsequent resistance to hormonal therapies. Alterations in the AR signaling pathway have been observed in certain selection contexts and contribute to the resistance to agents that target hormonal regulation of the AR, including standard androgen deprivation therapy, antiandrogens such as enzalutamide, and androgen synthesis inhibition with abiraterone acetate. One such resistance mechanism is the synthesis of constitutively active AR variants lacking the canonical ligand-binding domain. This review focuses on the etiology, characterization, biological properties, and emerging data contributing to the clinical characteristics of AR variants, and suggests approaches to full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic.Keywords
This publication has 100 references indexed in Scilit:
- Constitutively Active Androgen Receptor Variants Upregulate Expression of Mesenchymal Markers in Prostate Cancer CellsPLOS ONE, 2013
- Overcoming mutation-based resistance to antiandrogens with rational drug designeLife, 2013
- Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cellsThe International Journal of Biochemistry & Cell Biology, 2013
- Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer InitiationCancer Cell, 2012
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1Cancer Cell, 2011
- A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activitiesThe Prostate, 2011
- Integrative Genomic Profiling of Human Prostate CancerCancer Cell, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Nuclear Receptor-Induced Chromosomal Proximity and DNA Breaks Underlie Specific Translocations in CancerCell, 2009
- Pleiotropic functional properties of androgen receptor mutants in prostate cancerHuman Mutation, 2008